These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 29534286)

  • 21. Population Pharmacokinetics and Pharmacodynamics of the Calcimimetic Etelcalcetide in Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis.
    Chen P; Olsson Gisleskog P; Perez-Ruixo JJ; Xiao J; Wilkins J; Narayanan A; Gibbs JP; Melhem M
    CPT Pharmacometrics Syst Pharmacol; 2016 Sep; 5(9):484-94. PubMed ID: 27639083
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Calcimimetic use in US hemodialysis facilities in first 2 years after the launch of etelcalcetide: A descriptive analysis of real-world clinical practice and outcomes.
    Stephens JM; Fox KM; Desai P; Cheng S; Goodman WG; Kendrick JB
    Hemodial Int; 2022 Apr; 26(2):243-254. PubMed ID: 34931443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase 1, single-dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of etelcalcetide in pediatric patients with secondary hyperparathyroidism receiving hemodialysis.
    Sohn W; Salusky IB; Schmitt CP; Taylan C; Walle JV; Ngang J; Yan L; Kroenke M; Warady BA
    Pediatr Nephrol; 2021 Jan; 36(1):133-142. PubMed ID: 32647975
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved Control of Secondary Hyperparathyroidism in Hemodialysis Patients Switching from Oral Cinacalcet to Intravenous Etelcalcetide, Especially in Nonadherent Patients.
    Xipell M; Montagud-Marrahi E; Rubio MV; Ojeda R; Arias-Guillén M; Fontseré N; Rodas L; Vera M; Broseta JJ; Torregrosa V; Filella X; Maduell F
    Blood Purif; 2019; 48(2):106-114. PubMed ID: 30699421
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current therapeutic options for the treatment of secondary hyperparathyroidism in end-stage renal disease patients treated with hemodialysis: a 12-month comparative study.
    Dudar I; Shifris I; Dudar S; Kulish V
    Pol Merkur Lekarski; 2022 Oct; 50(299):294-298. PubMed ID: 36283011
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Etelcalcetide Utilization, Dosing Titration, and Chronic Kidney Disease-Mineral and Bone Disease (CKD-MBD) Marker Responses in US Hemodialysis Patients.
    Karaboyas A; Muenz D; Fuller DS; Desai P; Lin TC; Robinson BM; Rossetti S; Pisoni RL
    Am J Kidney Dis; 2022 Mar; 79(3):362-373. PubMed ID: 34273436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Etelcalcetide, A Novel Calcimimetic, Prevents Vascular Calcification in A Rat Model of Renal Insufficiency with Secondary Hyperparathyroidism.
    Yu L; Tomlinson JE; Alexander ST; Hensley K; Han CY; Dwyer D; Stolina M; Dean C; Goodman WG; Richards WG; Li X
    Calcif Tissue Int; 2017 Dec; 101(6):641-653. PubMed ID: 29038882
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exploring the potential value of improved care for secondary hyperparathyroidism with a novel calcimimetic therapy.
    Stollenwerk B; Iannazzo S; Cooper K; Belozeroff V
    J Med Econ; 2017 Oct; 20(10):1110-1115. PubMed ID: 28803497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nonclinical Safety Profile of Etelcalcetide, a Novel Peptide Calcimimetic for the Treatment of Secondary Hyperparathyroidism.
    Fielden MR; Dean C; Black K; Sawant SG; Subramanian R; Tomlinson JE; Walter S; Zimmermann C; Griggs MW; McKeon ME; Lewis EM; Beevers C; Pyrah I
    Int J Toxicol; 2016 May; 35(3):294-308. PubMed ID: 26941242
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Etelcalcetide: injectable calcimimetic for the treatment of secondary hyperparathyroidism in hemodialysis-dependent patients.
    Ureña Torres PA; Bover J; Cohen-Solal M
    Drugs Today (Barc); 2017 Sep; 53(9):489-500. PubMed ID: 29238762
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Phase I, Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Etelcalcetide Administered Intravenously to Chinese Patients With Chronic Kidney Disease Undergoing Hemodialysis.
    Xing C; Chen J; Zuo L; Fang Y; Ding X; Ni Z; Kong C; Shi G; Lu H; Hellawell J; Cheng S; Sohn W
    Clin Ther; 2021 Nov; 43(11):2013-2023. PubMed ID: 34774334
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A 12-week dose-escalating study of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese hemodialysis patients
.
    Yokoyama K; Fukagawa M; Shigematsu T; Akiba T; Fujii A; Odani M; Akizawa T
    Clin Nephrol; 2017 Aug; 88(2):68-78. PubMed ID: 28671062
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of secondary hyperparathyroidism: How do cinacalcet and etelcalcetide differ?
    Eidman KE; Wetmore JB
    Semin Dial; 2018 Sep; 31(5):440-444. PubMed ID: 30009474
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of etelcalcetide on cardiac hypertrophy in hemodialysis patients: a randomized controlled trial (ETECAR-HD).
    Dörr K; Kammer M; Reindl-Schwaighofer R; Lorenz M; Loewe C; Marculescu R; Erben R; Oberbauer R
    Trials; 2019 Oct; 20(1):601. PubMed ID: 31651370
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients.
    Shigematsu T; Shimazaki R; Fukagawa M; Akizawa T;
    Clin Exp Nephrol; 2019 Feb; 23(2):258-267. PubMed ID: 30159688
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects.
    Martin KJ; Bell G; Pickthorn K; Huang S; Vick A; Hodsman P; Peacock M
    Nephrol Dial Transplant; 2014 Feb; 29(2):385-92. PubMed ID: 24235081
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide.
    Cozzolino M; Galassi A; Conte F; Mangano M; Di Lullo L; Bellasi A
    Ther Clin Risk Manag; 2017; 13():679-689. PubMed ID: 28615947
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determination of Etelcalcetide Biotransformation and Hemodialysis Kinetics to Guide the Timing of Its Dosing.
    Edson KZ; Wu BM; Iyer A; Goodman W; Skiles GL; Subramanian R
    Kidney Int Rep; 2016 May; 1(1):24-33. PubMed ID: 29318205
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathyroidism.
    Li X; Yu L; Asuncion F; Grisanti M; Alexander S; Hensley K; Han CY; Niu QT; Dwyer D; Villasenor K; Stolina M; Dean C; Ominsky MS; Ke HZ; Tomlinson JE; Richards WG
    Bone; 2017 Dec; 105():163-172. PubMed ID: 28867373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.